Ryan A Maddox1, J L Blase2, N D Mercaldo3, A R Harvey2, L B Schonberger2, W A Kukull4, E D Belay2. 1. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA rmaddox@cdc.gov. 2. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. Department of Biostatistics, Vanderbilt University, Nashville, TN, USA National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA. 4. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Brain tissue analysis is necessary to confirm prion diseases. Clinically unsuspected cases may be identified through neuropathologic testing. METHODS: National Alzheimer's Coordinating Center (NACC) Minimum and Neuropathologic Data Set for 1984 to 2005 were reviewed. Eligible patients had dementia, underwent autopsy, had available neuropathologic data, belonged to a currently funded Alzheimer's Disease Center (ADC), and were coded as having an Alzheimer's disease clinical diagnosis or a nonprion disease etiology. For the eligible patients with neuropathology indicating prion disease, further clinical information, collected from the reporting ADC, determined whether prion disease was considered before autopsy. RESULTS: Of 6000 eligible patients in the NACC database, 7 (0.12%) were clinically unsuspected but autopsy-confirmed prion disease cases. CONCLUSION: The proportion of patients with dementia with clinically unrecognized but autopsy-confirmed prion disease was small. Besides confirming clinically suspected cases, neuropathology is useful to identify unsuspected clinically atypical cases of prion disease.
BACKGROUND: Brain tissue analysis is necessary to confirm prion diseases. Clinically unsuspected cases may be identified through neuropathologic testing. METHODS: National Alzheimer's Coordinating Center (NACC) Minimum and Neuropathologic Data Set for 1984 to 2005 were reviewed. Eligible patients had dementia, underwent autopsy, had available neuropathologic data, belonged to a currently funded Alzheimer's Disease Center (ADC), and were coded as having an Alzheimer's disease clinical diagnosis or a nonprion disease etiology. For the eligible patients with neuropathology indicating prion disease, further clinical information, collected from the reporting ADC, determined whether prion disease was considered before autopsy. RESULTS: Of 6000 eligible patients in the NACC database, 7 (0.12%) were clinically unsuspected but autopsy-confirmed prion disease cases. CONCLUSION: The proportion of patients with dementia with clinically unrecognized but autopsy-confirmed prion disease was small. Besides confirming clinically suspected cases, neuropathology is useful to identify unsuspected clinically atypical cases of prion disease.
Authors: S Poser; B Mollenhauer; A Kraubeta; I Zerr; B J Steinhoff; A Schroeter; M Finkenstaedt; W J Schulz-Schaeffer; H A Kretzschmar; K Felgenhauer Journal: Brain Date: 1999-12 Impact factor: 13.501
Authors: E J Cochran; D A Bennett; L Cervenáková; K Kenney; B Bernard; N L Foster; D F Benson; L G Goldfarb; P Brown Journal: Neurology Date: 1996-09 Impact factor: 9.910
Authors: Numthip Chitravas; Richard S Jung; Diane M Kofskey; Janis E Blevins; Pierluigi Gambetti; R John Leigh; Mark L Cohen Journal: Ann Neurol Date: 2011-06-14 Impact factor: 10.422
Authors: Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: H J Tschampa; M Neumann; I Zerr; K Henkel; A Schröter; W J Schulz-Schaeffer; B J Steinhoff; H A Kretzschmar; S Poser Journal: J Neurol Neurosurg Psychiatry Date: 2001-07 Impact factor: 10.154
Authors: Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen Journal: Arch Neurol Date: 2009-02
Authors: Eva Bagyinszky; Vo Van Giau; Young Chul Youn; Seong Soo A An; SangYun Kim Journal: Neuropsychiatr Dis Treat Date: 2018-08-14 Impact factor: 2.570